trial

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

NCTId NCT01614912
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 284 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2015-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
284 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-08
Primary completion
2015-05
Eligibility
ALL · 18 Years · 74 Years

Interventions & indications

Drugs
SM-13496

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Sites

4 total
Tokyo, Etc, JapanKuala Lumpur, Etc, MalaysiaSeoul, Etc, South KoreaTaipei, Etc, Taiwan

Linked catalysts

1
Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizoph — primary completion2015-05

Facts & assertions

4 sourced
Enrollment
284
Phase
PHASE3
Primary Completion Date
2015-05
Status
COMPLETED
relationships
The graph out of here
drug
SM-13496
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication